In the development of nutraceuticals and functional foods, bioavailability is often regarded as a primary quality indicator. Higher absorption is commonly associated with superior efficacy, lower dosages, and better consumer compliance. But this raises a critical question: are we formulating to maximize a pharmacokinetic data point or for real biological efficacy?
For many nutrients and bioactive compounds, the high-bioavailability approach is justified. Poorly absorbed substances, such as certain minerals, vitamins, and botanical derivatives like curcumin and berberine, benefit from delivery systems designed to optimize physiological effects and limit adverse reactions. However, a growing body of scientific evidence suggests that maximizing bioavailability is not always the most effective strategy. Efficacy often depends more on how bioactive compounds interact with the intestinal environment, the microbiota, and the organism as a whole.
The Role of the Gut Microbiota in Bioactivity
One of the most significant shifts in recent years is the recognition of the interplay between secondary metabolites, such as polyphenols, and the gut microbiota. Many polyphenols are poorly absorbed in their native form due to modifications within the digestive tract. Variations in pH, digestive enzymes, and microbial metabolism can profoundly alter the chemical structure of plant derivatives and, consequently, their biological activity.
Using whole-food botanicals allows formulators to leverage the “matrix effect” provided by natural fibers, which help protect bioactive compounds from premature degradation during gastrointestinal transit. Furthermore, many plant compounds occur naturally as glycosides (bound to sugars). This configuration allows specific polyphenols to be released directly in the gut when bacterial metabolism or specific enzymes trigger their cleavage, as seen with isoflavones, anthocyanins, and flavonoids. This natural strategy grants compounds higher water solubility and partial protection during the early stages of digestion. Once they reach the colon, microbial metabolism releases the active aglycones, making them more readily available.
Simultaneously, certain phyto-derivatives exert antimicrobial or modulating effects on the microbiota or are further transformed by intestinal microorganisms. This process generates a variety of microbial metabolites that can reach high concentrations in the colon and, in part, enter systemic circulation. These metabolites may represent the key link between polyphenol intake and their observed health benefits. Understanding this microbial impact is fundamental to interpreting the true bioavailability of bioactive compounds. In many cases, biological activity is not driven by the original compound, but by the metabolites generated by the microbiota.
Bioaccessibility: The Importance of the Food Matrix
Bioavailability is not just about plasma concentration; it is deeply rooted in what happens within the digestive tract. Before absorption can occur, compounds must become bioaccessible, meaning they must be released from the food matrix during digestion. Several factors influence this process, including:
- Caloric content
- Presence of fats and proteins
- Meal volume
- Gastric emptying rate
Studies have shown, for instance, that isoflavonoids are better absorbed when consumed with foods containing fats and proteins, and carotenoid absorption increases significantly during high-fat meals. Conversely, some supplements taken on an empty stomach may exhibit lower bioavailability than when taken with a meal. This demonstrates that the nutritional context significantly modulates the functional performance of bioactives. Consequently, usage instructions (e.g., “take with food”) are not just labels but critical elements of nutraceutical product design.
When Limited Absorption is a Functional Advantage
Not all applications require maximum systemic exposure. Ingredients intended to support:
- Intestinal health,
- Microbiota modulation,
- Local immune regulation and
- Digestive function
can actually benefit from controlled or limited absorption. Keeping active compounds within the intestinal environment fosters their interaction with the microbiota and gut tissues, enhancing functional outcomes. In cases like essential oils or specific phyto-derivatives, local activity can be more relevant than plasma concentration.
From “Maximizing Absorption” to “Optimizing Function”
Modern nutraceutical science is moving beyond the simplistic “more is better” approach. Today, effective formulation requires a systemic perspective that considers:
- Bioaccessibility
- Microbial metabolism
- Food matrix effects
- Target site of action
The key question is no longer “How can we maximize absorption?” but rather
“How can we optimize biological function?”
Toward Next-Generation Functional Products
The next generation of nutraceuticals will increasingly rely on targeted delivery systems, controlled bioavailability, microbiota-aware formulations, and personalized nutrition strategies. By aligning bioavailability design with physiological and microbial mechanisms, we can develop products that deliver consistent, meaningful, and measurable health benefits.
Read More
Rein MJ, Renouf M, Cruz-Hernandez C, Actis-Goretta L, Thakkar SK, da Silva Pinto M. Bioavailability of bioactive food compounds: a challenging journey to bioefficacy. Br J Clin Pharmacol. 2013 Mar;75(3):588-602. doi: 10.1111/j.1365-2125.2012.04425.x. PMID: 22897361; PMCID: PMC3575927.
